Exact Mass: 489.1536
Exact Mass Matches: 489.1536
Found 271 metabolites which its exact mass value is equals to given mass value 489.1536
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
(1S,2S,3R,5S,8R,9R,10R)-10-[(2R,3E,5E,7E)-7-(2,4-dioxopyrrolidin-3-ylidene)-7-hydroxy-4-methylhepta-3,5-dien-2-yl]-3,5,9-trimethyl-7-oxo-4,11,12-trioxatricyclo[6.3.1.01,5]dodecane-2-carboxylic acid
4-Hydroxy duloxetine glucuronide
4-Hydroxy duloxetine glucuronide is a metabolite of duloxetine. Duloxetine (sold under the brand names Cymbalta, Ariclaim, Xeristar, Yentreve, Duzela) is a serotonin-norepinephrine reuptake inhibitor (SNRI) manufactured and marketed by Eli Lilly. It is effective for major depressive disorder and generalized anxiety disorder (GAD). (Wikipedia)
3-Benzyl-1-(1H-imidazol-4-ylmethyl)-4-(thien-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-7-carbonitrile
Gemigliptin
(2S)-3-[3-[(4-Carbamimidoylbenzoyl)amino]propanoylamino]-2-[(4-ethylphenyl)sulfonylamino]propanoic acid
O1-[2-(2-amino-4-oxo-3,4-dihydro-pteridin-6-yl)-1-(1,2,3-dihydroxy-propyl)-ethyl]-beta-D-glucopyranuronic acid
8-2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-deoxyguanosine
Cys Cys His Lys
Cys Cys His Gln
Cys Cys Lys His
Cys Cys Gln His
Cys Asp Pro Arg
Cys Asp Arg Pro
Cys His Cys Lys
Cys His Cys Gln
Cys His Lys Cys
Cys His Gln Cys
Cys Lys Cys His
Cys Lys His Cys
Cys Pro Asp Arg
Cys Pro Arg Asp
Cys Gln Cys His
Cys Gln His Cys
Cys Arg Asp Pro
Cys Arg Pro Asp
Asp Cys Pro Arg
Asp Cys Arg Pro
Asp Met Pro Gln
Asp Met Gln Pro
Asp Asn Asn Gln
Asp Asn Gln Asn
Asp Pro Cys Arg
Asp Pro Met Gln
Asp Pro Gln Met
Asp Pro Arg Cys
Asp Gln Met Pro
Asp Gln Asn Asn
Asp Gln Pro Met
Asp Arg Cys Pro
Asp Arg Pro Cys
Glu Met Asn Pro
Glu Met Pro Asn
Glu Asn Met Pro
Glu Asn Asn Asn
Glu Asn Pro Met
Glu Pro Met Asn
Glu Pro Asn Met
Gly His Asn Tyr
Gly His Tyr Asn
Gly Asn His Tyr
Gly Asn Asn Trp
Gly Asn Trp Asn
Gly Asn Tyr His
Gly Trp Asn Asn
Gly Tyr His Asn
Gly Tyr Asn His
His Cys Cys Lys
His Cys Cys Gln
His Cys Lys Cys
His Cys Gln Cys
His Gly Asn Tyr
His Gly Tyr Asn
His Lys Cys Cys
His Asn Gly Tyr
His Asn Tyr Gly
His Gln Cys Cys
His Tyr Gly Asn
His Tyr Asn Gly
Lys Cys Cys His
Lys Cys His Cys
Lys His Cys Cys
Met Asp Pro Gln
Met Asp Gln Pro
Met Glu Asn Pro
Met Glu Pro Asn
Met Asn Glu Pro
Met Asn Pro Glu
Met Pro Asp Gln
Met Pro Glu Asn
Met Pro Asn Glu
Met Pro Gln Asp
Met Gln Asp Pro
Met Gln Pro Asp
Asn Asp Asn Gln
Asn Asp Gln Asn
Asn Glu Met Pro
Asn Glu Asn Asn
Asn Glu Pro Met
Asn Gly His Tyr
Asn Gly Asn Trp
Asn Gly Trp Asn
Asn Gly Tyr His
Asn His Gly Tyr
Asn His Tyr Gly
Asn Met Glu Pro
Asn Met Pro Glu
Asn Asn Asp Gln
Asn Asn Glu Asn
Asn Asn Gly Trp
Asn Asn Asn Glu
Asn Asn Gln Asp
Asn Asn Trp Gly
Asn Pro Glu Met
Asn Pro Met Glu
Asn Gln Asp Asn
Asn Gln Asn Asp
Asn Trp Gly Asn
Asn Trp Asn Gly
Asn Tyr Gly His
Asn Tyr His Gly
Pro Cys Asp Arg
Pro Cys Arg Asp
Pro Asp Cys Arg
Pro Asp Met Gln
Pro Asp Gln Met
Pro Asp Arg Cys
Pro Glu Met Asn
Pro Glu Asn Met
Pro Met Asp Gln
Pro Met Glu Asn
Pro Met Asn Glu
Pro Met Gln Asp
Pro Asn Glu Met
Pro Asn Met Glu
Pro Gln Asp Met
Pro Gln Met Asp
Pro Arg Cys Asp
Pro Arg Asp Cys
Gln Cys Cys His
Gln Cys His Cys
Gln Asp Met Pro
Gln Asp Asn Asn
Gln Asp Pro Met
Gln His Cys Cys
Gln Met Asp Pro
Gln Met Pro Asp
Gln Asn Asp Asn
Gln Asn Asn Asp
Gln Pro Asp Met
Gln Pro Met Asp
Arg Cys Asp Pro
Arg Cys Pro Asp
Arg Asp Cys Pro
Arg Asp Pro Cys
Arg Pro Cys Asp
Arg Pro Asp Cys
Trp Gly Asn Asn
Trp Asn Gly Asn
Trp Asn Asn Gly
Tyr Gly His Asn
Tyr Gly Asn His
Tyr His Gly Asn
Tyr His Asn Gly
Tyr Asn Gly His
Tyr Asn His Gly
N-(4-acetamidophenyl)-Indomethacin amide
BMS 214662
C471 - Enzyme Inhibitor > C2020 - Farnesyl Transferase Inhibitor
5-chloro-2-[2-[4-[(2-cyanoethyl)methylamino]phenyl]vinyl]-1,3,3-trimethyl-3H-indolium methyl sulphate
1,2,4-Benzotriazin-3-amine, 7-(2-chloro-5-Methoxyphenyl)-5-Methyl-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-
1-Octyl-2,3-dimethylimidazolium bis(trifluoromethanesulfonyl)imide
d-galactose 1-[2-(2-azidoethoxy)ethoxyethyl]-2,3,4,6-tetra-o-acetate
3-(3-amino-3-oxopropyl)-2-[[1-methyl-2-(p-tolyl)-1H-indol-3-yl]azo]benzothiazolium chloride
2-(4-METHYLUMBELLIFERYL)-α-D-N-ACETYLNEURAMINIC ACID SODIUM SALT
[(2R)-1-[6-(propan-2-yloxycarbonylamino)purin-9-yl]propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphinic acid
tert-Butyl (2S,5S)-2-(9-chloro-1,11-dihydroisochromeno[4,3:6,7]naphtho[1,2-d]imidazol-2-yl)-5-(methyl)pyrrolidine-1-carboxylate
Gemigliptin
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
PRX-07034 hydrochloride
PRX-07034 hydrochloride is a highly selective and potent 5-HT6 receptor antagonist with a Ki= 4-8 nM and an IC50 of 19 nM. PRX-07034 can be used for the research of enhancing working memory and cognitive flexibility[1].
(2S,3S,4R,5R)-2-(5-tert-Butyl-1,3,4-oxadiazol-2-yl)-5-(6-(4-chloro-2-fluoro-anilino)purin-9-yl)tetrahydrofuran-3,4-diol
1-((1H-Imidazol-5-yl)methyl)-3-benzyl-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-7-carbonitrile
5-(benzenesulfonyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-ethylbenzenesulfonamide
N-[4-bromo-2-[[(2-hydrazinyl-2-oxoethyl)amino]-phenylmethyl]phenyl]-3-(4-morpholinyl)propanamide
[9-(4-Ethoxyphenyl)sulfonyl-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-8-yl]-(4-methylphenyl)methanone
2-[5-Methanesulfonylamino-2-(4-aminophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-n-(3,3,3-trifluoro-1-isopropyl-2-oxopropyl)acetamide
Citicoline
Citicoline is an essential intermediate in the biosynthetic pathway of structural phospholipids in cell membranes, particularly phosphatidylcholine. Once absorbed, citicoline is widely distributed throughout the body, crosses the blood-brain barrier and reaches the central nervous system (CNS), where it is incorporated into the membrane and microsomal phospholipid fraction. Citicoline activates biosynthesis of structural phospholipids of neuronal membranes, increases brain metabolism, and acts upon the levels of different neurotransmitters. Thus, citicoline has been experimentally shown to increase norepinephrine and dopamine levels in the CNS. Owing to these pharmacological mechanisms, citicoline has a neuroprotective effect in hypoxic and ischemic conditions, decreasing the volume of ischemic lesion, and also improves learning and memory performance in animal models of brain aging. In addition, citicoline has been shown to restore the activity of mitochondrial ATPase and membrane Na+/K+ATPase, to inhibit activation of certain phospholipases, and to accelerate reabsorption of cerebral edema in various experimental models. Citicoline has also been shown to be able to inhibit mechanisms of apoptosis associated to cerebral ischemia and in certain neurodegeneration models, and to potentiate neuroplasticity mechanisms. Citicoline is a safe drug, as shown by the toxicological tests conducted, that has no significant systemic cholinergic effects and is a well tolerated product. (PMID: 17171187) [HMDB]. Citicoline is found in many foods, some of which are chives, black walnut, kohlrabi, and abiyuch. Citicoline is an essential intermediate in the biosynthetic pathway of structural phospholipids in cell membranes, particularly phosphatidylcholine. Once absorbed, citicoline is widely distributed throughout the body, crosses the blood-brain barrier and reaches the central nervous system (CNS), where it is incorporated into the membrane and microsomal phospholipid fraction. Citicoline activates biosynthesis of structural phospholipids of neuronal membranes, increases brain metabolism, and acts upon the levels of different neurotransmitters. Thus, citicoline has been experimentally shown to increase norepinephrine and dopamine levels in the CNS. Owing to these pharmacological mechanisms, citicoline has a neuroprotective effect in hypoxic and ischemic conditions, decreasing the volume of ischemic lesion, and also improves learning and memory performance in animal models of brain aging. In addition, citicoline has been shown to restore the activity of mitochondrial ATPase and membrane Na+/K+ATPase, to inhibit activation of certain phospholipases, and to accelerate reabsorption of cerebral edema in various experimental models. Citicoline has also been shown to be able to inhibit mechanisms of apoptosis associated to cerebral ischemia and in certain neurodegeneration models, and to potentiate neuroplasticity mechanisms. Citicoline is a safe drug, as shown by the toxicological tests conducted, that has no significant systemic cholinergic effects and is a well tolerated product. (PMID:17171187). N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics D002491 - Central Nervous System Agents > D018697 - Nootropic Agents
(2R,3R,4S,7S)-7-(2-bromo-5-hydroxyphenyl)-3-[(3R,4R)-3,4-dihydroxypentanoyl]oxy-7-methoxy-2,4-dimethylheptanoate
(3R,5S,9R,10R)-10-[(2R,3E,5E,7Z)-7-(2,4-dioxopyrrolidin-3-ylidene)-7-hydroxy-4-methylhepta-3,5-dien-2-yl]-3,5,9-trimethyl-7-oxo-4,11,12-trioxatricyclo[6.3.1.01,5]dodecane-2-carboxylic acid
4-Amino-1-{5-O-[hydroxy({hydroxy[2-(trimethylazaniumyl)ethoxy]phosphoryl}oxy)phosphoryl]pentofuranosyl}pyrimidin-2(1H)-one
(2S)-3-[3-[(4-Carbamimidoylbenzoyl)amino]propanoylamino]-2-[(4-ethylphenyl)sulfonylamino]propanoic acid
4-[(2-bromophenoxy)methyl]-N-[4-[(3,5-dimethyl-1-pyrazolyl)methyl]phenyl]benzamide
4-[[3-[(4-Chlorophenyl)sulfonylamino]-2-quinoxalinyl]amino]-1-piperidinecarboxylic acid ethyl ester
N-(3-hydroxyphenyl)-2-[[4-methyl-5-[4-(4-morpholinylsulfonyl)phenyl]-1,2,4-triazol-3-yl]thio]acetamide
3-[[4-(1-benzotriazolyl)-1-piperidinyl]sulfonyl]-N-cyclopentylbenzenesulfonamide
4-[3-[(3-chloro-4-fluoroanilino)-oxomethyl]-7-oxo-1H-pyrazolo[1,5-a]pyrimidin-5-yl]-1-piperidinecarboxylic acid tert-butyl ester
1-[(4-chlorophenyl)-oxomethyl]-N-[4-(1-piperidinylsulfonyl)phenyl]-3-piperidinecarboxamide
nocamycin E
An organic heterotricyclic compound and tetramic acid derivative isolated from a mutant strain of Saccharothrix syringae. Nocamycin E exhibits considerably lower antibacterial activity than the corresponding methyl ester, nocamycin I.
N-[[3-(4-carboxybutyl)-5-chloro-3,4-dihydro-8-hydroxy-1-oxo-1H-2-benzopyran-7-yl]carbonyl]-L-phenylalanine
(1S,9R,10R,11R)-12-acetyl-10-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-5-pyrimidin-5-yl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1R,9S,10S,11S)-5-(3-fluorophenyl)-10-(hydroxymethyl)-12-methylsulfonyl-11-(piperidine-1-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
(2R,3R,3aS,9bS)-1-(1,3-benzodioxol-5-ylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-7-pyrimidin-5-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(1S,9R,10R,11R)-5-(3-fluorophenyl)-10-(hydroxymethyl)-12-methylsulfonyl-11-(piperidine-1-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
(1R,9S,10S,11S)-12-acetyl-10-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-5-pyrimidin-5-yl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1R,9S,10S,11S)-10-(hydroxymethyl)-5-(4-methoxyphenyl)-N,N-dimethyl-6-oxo-12-(pyrazine-2-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(2S,3S,3aR,9bR)-1-(1,3-benzodioxol-5-ylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-7-pyrimidin-5-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
4-fluoro-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
4-fluoro-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
[(3aR,4R,9bR)-1-(3-methoxyphenyl)sulfonyl-5-methyl-8-[2-(3-pyridinyl)ethynyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-4-yl]methanol
[(3aS,4S,9bS)-1-(3-methoxyphenyl)sulfonyl-5-methyl-8-[2-(3-pyridinyl)ethynyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-4-yl]methanol
(6R,7R,8R)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8S)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
N-[[(2R,3S)-8-[2-(3-fluorophenyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylmethanesulfonamide
4-fluoro-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
4-fluoro-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
4-fluoro-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
4-fluoro-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
4-fluoro-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
4-fluoro-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
(1S,9R,10R,11R)-10-(hydroxymethyl)-5-(4-methoxyphenyl)-N,N-dimethyl-6-oxo-12-(pyrazine-2-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
[(3aS,4R,9bS)-1-(3-methoxyphenyl)sulfonyl-5-methyl-8-[2-(3-pyridinyl)ethynyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-4-yl]methanol
(6R,7S,8S)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7R,8R)-N-(2,5-difluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
[(2R,3S,4R,5R)-5-[2-amino-5-[[[(1S,4S,5R)-4,5-dihydroxycyclopent-2-en-1-yl]amino]methyl]-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
JNJ-42226314
JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain[1].